Pfizer: progress report in oncology

(CercleFinance.com) - Pfizer announces that it will present the latest results from its genitourinary (GU) portfolio at the American Society of Clinical Oncology GU Cancer Symposium (ASCO GU) in San Francisco from 13 to 15 February.


The data comes from over 20 company-supported research projects, including five oral presentations, highlighting advances in the treatment of prostate and bladder cancer.

Among the key presentations, the laboratory will unveil results in metastatic castration-resistant prostate cancer, as well as treatments in development for various types of bladder cancer, including disitamab vedotin and sasanlimab.


Copyright (c) 2025 CercleFinance.com. All rights reserved.